The Korean Journal of Pain

  • 제29권3호
  • /
  • Pages.153-157
  • /
  • 2016
  • /
  • 2005-9159(pISSN)
  • /
  • 2093-0569(eISSN)
대한통증학회 (The Korean Pain Society)
권호 표지
DOI QR코드

DOI QR Code

Tapentadol: Can It Kill Two Birds with One Stone without Breaking Windows?

  • Chang, Eun Jung (Department of Anesthesia and Pain Medicine, School of Medicine, Pusan National University) ;
  • Choi, Eun Ji (Department of Anesthesia and Pain Medicine, School of Medicine, Pusan National University) ;
  • Kim, Kyung Hoon (Department of Anesthesia and Pain Medicine, School of Medicine, Pusan National University)
  • 투고 : 2016.06.21
  • 심사 : 2016.06.28
  • 발행 : 2016.07.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Tapentadol is a novel oral analgesic with a dual mode of action as an agonist of the ${\mu}$-opioid receptor (MOR), and as a norepinephrine reuptake inhibitor (NRI) all in a single molecule. Immediate release (IR) tapentadol shows its analgesic effect quickly, at around 30 minutes. Its MOR agonistic action produces acute nociceptive pain relief; its role as an NRI brings about chronic neuropathic pain relief. Absorption is rapid, with a mean maximal serum concentration at 1.25-1.5 h after oral intake. It is present primarily in the form of conjugated metabolites after glucuronidation, and excretes rapidly and completely via the kidneys. The most common adverse reactions are nausea, dizziness, vomiting, and somnolence. Constipation is more common in use of the ER formulation. Precautions against concomitant use of central nervous system depressants, including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, and alcohol, or use of tapentadol within 14 days of the cessation of monoamine oxidase inhibitors, are advised. The safety and efficacy have not been established for use during pregnancy, labor, and delivery, or for nursing mothers, pediatric patients less than 18 years of age, and cases of severe renal impairment and severe hepatic impairment. The major concerns for tapentadol are abuse, addiction, seeking behavior, withdrawal, and physical dependence. The presumed problem for use of tapentadol is to control the ratio of MOR agonist and NRI. In conclusion, tapentadol produces both nociceptive and neuropathic pain relief, but with worries about abuse and dependence.

키워드

참고문헌

  1. Lassen D, Damkier P, Brosen K. The pharmacogenetics of tramadol. Clin Pharmacokinet 2015; 54: 825-36. https://doi.org/10.1007/s40262-015-0268-0
  2. Farquhar-Smith P, Gubbay A. Tramadol and acetaminophen combination for chronic non-cancer pain. Expert Opin Pharmacother 2013; 14: 2297-304. https://doi.org/10.1517/14656566.2013.839985
  3. Kress HG. Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon? Eur J Pain 2010; 14: 781-3. https://doi.org/10.1016/j.ejpain.2010.06.017
  4. Dart RC, Bartelson BB, Adams EH. Nonmedical use of tapentadol immediate release by college students. Clin J Pain 2014; 30: 685-92. https://doi.org/10.1097/AJP.0000000000000001
  5. Dart RC, Cicero TJ, Surratt HL, Rosenblum A, Bartelson BB, Adams EH. Assessment of the abuse of tapentadol immediate release: the first 24 months. J Opioid Manag 2012; 8: 395-402. https://doi.org/10.5055/jom.2012.0139
  6. Buschmann H. Chapter 12 Tapentadol - from morphine and tramadol to the discovery of tapentadol. In: Analogue-based drug discovery III. Edited by Fischer J, Ganellin CR, Rotella DP. Weinheim, Wiley-VCH. 2013, pp 295-318.
  7. Wade WE, Spruill WJ. Tapentadol hydrochloride: a centrally acting oral analgesic. Clin Ther 2009; 31: 2804-18. https://doi.org/10.1016/j.clinthera.2009.12.003
  8. Smyth LA, Collins I. Measuring and interpreting the selectivity of protein kinase inhibitors. J Chem Biol 2009; 2: 131-51. https://doi.org/10.1007/s12154-009-0023-9
  9. Tzschentke TM, Folgering JH, Flik G, De Vry J. Tapentadol increases levels of noradrenaline in the rat spinal cord as measured by in vivo microdialysis. Neurosci Lett 2012; 507: 151-5. https://doi.org/10.1016/j.neulet.2011.12.008
  10. Ramaswamy S, Chang S, Mehta V. Tapentadol--the evidence so far. Anaesthesia 2015; 70: 518-22. https://doi.org/10.1111/anae.13080
  11. Ok YM, Cheon JH, Choi EJ, Chang EJ, Lee HM, Kim KH. Nefopam reduces dysesthesia after percutaneous endoscopic lumbar discectomy. Korean J Pain 2016; 29: 40-7. https://doi.org/10.3344/kjp.2016.29.1.40
  12. Kim KH, Abdi S. Rediscovery of nefopam for the treatment of neuropathic pain. Korean J Pain 2014; 27: 103-11. https://doi.org/10.3344/kjp.2014.27.2.103
  13. Barber J. Examining the use of tramadol hydrochloride as an antidepressant. Exp Clin Psychopharmacol 2011; 19: 123-30. https://doi.org/10.1037/a0022721
  14. Terlinden R, Ossig J, Fliegert F, Lange C, Gohler K. Absorption, metabolism, and excretion of 14C-labeled tapentadol HCl in healthy male subjects. Eur J Drug Metab Pharmacokinet 2007; 32: 163-9. https://doi.org/10.1007/BF03190478
  15. Singh DR, Nag K, Shetti AN, Krishnaveni N. Tapentadol hydrochloride: a novel analgesic. Saudi J Anaesth 2013; 7: 322-6. https://doi.org/10.4103/1658-354X.115319
  16. Park CH. Comparison of morphine and tramadol in transforaminal epidural injections for lumbar radicular pain. Korean J Pain 2013; 26: 265-9. https://doi.org/10.3344/kjp.2013.26.3.265
  17. Xu XS, Smit JW, Lin R, Stuyckens K, Terlinden R, Nandy P. Population pharmacokinetics of tapentadol immediate release (IR) in healthy subjects and patients with moderate or severe pain. Clin Pharmacokinet 2010; 49: 671-82. https://doi.org/10.2165/11535390-000000000-00000
  18. Afilalo M, Etropolski MS, Kuperwasser B, Kelly K, Okamoto A, Van Hove I, et al. Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study. Clin Drug Investig 2010; 30: 489-505. https://doi.org/10.2165/11533440-000000000-00000
  19. Cepeda MS, Fife D, Ma Q, Ryan PB. Comparison of the risks of opioid abuse or dependence between tapentadol and oxycodone: results from a cohort study. J Pain 2013; 14: 1227-41. https://doi.org/10.1016/j.jpain.2013.05.010
  20. Cepeda MS, Fife D, Vo L, Mastrogiovanni G, Yuan Y. Comparison of opioid doctor shopping for tapentadol and oxycodone: a cohort study. J Pain 2013; 14: 158-64. https://doi.org/10.1016/j.jpain.2012.10.012
  21. Dart RC, Surratt HL, Le Lait MC, Stivers Y, Bebarta VS, Freifeld CC, et al. Diversion and illicit sale of extended release tapentadol in the United States. Pain Med. Forthcoming 2015.
  22. Butler SF, McNaughton EC, Black RA. Tapentadol abuse potential: a postmarketing evaluation using a sample of individuals evaluated for substance abuse treatment. Pain Med 2015; 16: 119-30. https://doi.org/10.1111/pme.12524
  23. McNaughton EC, Black RA, Weber SE, Butler SF. Assessing abuse potential of new analgesic medications following market release: an evaluation of internet discussion of tapentadol abuse. Pain Med 2015; 16: 131-40. https://doi.org/10.1111/pme.12547
  24. Vosburg SK, Jones JD, Manubay JM, Ashworth JB, Shapiro DY, Comer SD. A comparison among tapentadol tamperresistant formulations (TRF) and $OxyContin^{(R)}$ (non-TRF) in prescription opioid abusers. Addiction 2013; 108: 1095-106. https://doi.org/10.1111/add.12114

피인용 문헌

  1. Comparative pharmacology and toxicology of tramadol and tapentadol vol.22, pp.5, 2018, https://doi.org/10.1002/ejp.1196
  2. Cardiac Arrest Following Drug Abuse with Intravenous Tapentadol: Case Report and Literature Review vol.18, pp.None, 2016, https://doi.org/10.12659/ajcr.904695
  3. Opioid-induced constipation: a narrative review of therapeutic options in clinical management vol.32, pp.2, 2019, https://doi.org/10.3344/kjp.2019.32.2.69
  4. Tapentadol, the new kid on the block in India: Is it time to worry? vol.62, pp.6, 2020, https://doi.org/10.4103/psychiatry.indianjpsychiatry_332_20
  5. Dual μ-opioid receptor and norepinephrine reuptake mechanisms contribute to dezocine- and tapentadol-induced mechanical antiallodynia in cancer pain vol.876, pp.None, 2016, https://doi.org/10.1016/j.ejphar.2020.173062
  6. Repeated Administration of Clinical Doses of Tramadol and Tapentadol Causes Hepato- and Nephrotoxic Effects in Wistar Rats vol.13, pp.7, 2020, https://doi.org/10.3390/ph13070149
  7. Sublingual delivery of chondroitin sulfate conjugated tapentadol loaded nanovesicles for the treatment of osteoarthritis vol.31, pp.1, 2021, https://doi.org/10.1080/08982104.2020.1730400